School personnel information

写真b

SHIBAYAMA Hirohiko


Keyword

Hematology and Oncology

Mail Address

Mail Address

Laboratory Phone number

+81-6-6879-3871

URL

http://www.hematology.pro

Gender

Male

Organization 【 display / non-display

  • 2002.04.01 - 2007.03.31, Division of Internal Medicine, Graduate School of Medicine, Research Assistant

  • 2007.04.01 - 2010.05.31, Division of Internal Medicine, Graduate School of Medicine, Assistant Professor

  • 2010.06.01 - 2010.09.30, Division of Internal Medicine, Graduate School of Medicine, Associate Professor

  • 2010.10.01 - 2017.03.31, Division of Medicine, Graduate School of Medicine, Associate Professor

  • 2017.04.01 - , Division of Medicine, Graduate School of Medicine, Associate Professor

  • 2018.04.01 - , Osaka University

Education 【 display / non-display

Osaka University Faculty of Medicine  Graduated 1989.03

Employment Record 【 display / non-display

Osaka University Graduate School of Medicine, Department of Hematology and Oncology, associate professor 2010.06 - 2017.03

Research topics 【 display / non-display

  • Research for treatment of lymphoid malignancies by novel drugs
    Hematology and medical oncology-related

  • Analysis of Anamorsin and Picot as iron-sulfur proteins

Academic Society Membership 【 display / non-display

  • American Society of Clinical Oncology

 

Academic Papers 【 display / non-display

  • Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma. , Shibayama H, Teshima T, Choi I, Hataka K, Sekiguchi N, Yoshinari N. , J Clin Exp Hematopathology,59(4): 179-186, 2019.12, Papers

  • Endothelial Cell-Selective Adhesion Molecule Contributes to the Development of Definitive Hematopoiesis in the Fetal Liver. , Ueda T, Yokota T, Okuzaki D, Uno Y, Mashimo T, Kubota Y, Sudo T, Ishibashi T, Shingai Y, Doi Y, Ozawa T, Nakai R, Tanimura A, Ichii M, Ezoe S, Shibayama H, Oritani K, Kanakura Y. , Stem Cell Reports,13(6): 992-1005, 2019.12, Papers

  • Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation., Ueda T, Maeda T, Kusakabe S, Fujita J, Fukushima K, Yokota T, Shibayama H, Tomiyama Y, Kanakura Y., International Journal of Hematology,109(2):197-205, 2019.02, Papers

  • Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma., Maruyama D, Tsukasaki K, Uchida T, Maeda Y, Shibayama H, Nagai H, Kurosawa M, Suehiro Y, Hatake K, Ando K, Yoshida I, Hidaka M, Murayama T, Okitsu Y, Tsukamoto N, Taniwaki M, Suzumiya J, Tamura K, Yamauchi T, Ueda R, Tobinai K., Annals of Hematology,98(1):131-142, 2019.01, Papers

  • Ectonucleosidase CD39 Is Highly Expressed on ATLL Cells and Suppresses the Immune Response through theAdenosine Pathway., Yasuhiro Nagate, Sachiko Ezoe, Jiro Fujita, Takafumi Yokota, Michiko Ichii, Akira Tanimura, Yukiko Doi, Tomoaki Ueda, Jun Toda, Hirohiko Shibayama, Kenji Oritani, Yuzuru Kanakura, The American Society of Hematology 60th Annual Meeting,1, 2018.12, Other

display all >>

 

Lecture / Exhibition 【 display / non-display

  • Novartis Hematology Forum in Wakayama, 2017.12

  • Myeloma Seminar in Fukushima, 2017.09

  • PTCL Conference in Osaka, 2017.09

  • 4th Akita South Hospital hematology meeting, 2017.09

  • Multiple Myeloma Expert Seminar in Osaka, Treatment strategies for relapsed or refractory multiple myeloma, 2017.07

display all >>